Background-The efficacy of radiofrequency ablation for atrial fibrillation (AF) in patients with left ventricular (LV) systolic dysfunction and isolated diastolic dysfunction is uncertain. Methods and Results-A prospective cohort of patients with normal and abnormal LV function underwent ablation for antiarrhythmic drug (AAD)-refractory AF. Three groups were compared: 111 patients with systolic dysfunction, defined as LV ejection fraction (LVEF) Յ40%; 157 patients with isolated diastolic dysfunction but preserved LVEF Ն50%; and 100 patients with normal LV function. The primary end point was AAD-free AF elimination at 1 year after ablation. This end point was achieved in 62% of patients with systolic dysfunction, 75% of those with diastolic dysfunction, and 84% of controls (Pϭ0.007). AF control on or off AADs was achieved in 76% of patients with systolic dysfunction, 85% of those with diastolic dysfunction, and 89% of controls (Pϭ0.08).
A trial fibrillation (AF) and heart failure (HF) frequently coincide, often with deleterious hemodynamic and symptomatic consequences. In some patients, AF can result in symptomatic HF because of irregular and rapid ventricular response rates that lead to left ventricular (LV) systolic dysfunction. [1] [2] [3] Conversely, patients with systolic HF have a 6-fold increased, long-term (Ͼ5 year) risk of developing AF. 4 Even in patients with preserved LV systolic function, AF has been associated with LV diastolic dysfunction. One third of patients with HF related to isolated diastolic dysfunction present with AF. 5 In these patients with stiffened LV, the onset of AF results in a loss of the left atrial (LA) contribution to the LV that can be further compounded by the shortened diastolic filling times owing to rapid ventricular rates. In Ϸ10% of patients with abnormal LV diastolic function determined by echocardiography, new-onset AF develops during 4 years of follow-up. 6 Although AF frequently is associated with congestive heart failure, few data are available on the comparative efficacy of catheter ablation of AF in patients with various forms of LV dysfunction. For patients with systolic dysfunction, the data on AF ablation are limited but favorable. 7, 8 In patients with isolated LV diastolic dysfunction, no data are available on the efficacy of ablation. Therefore, the objective of the present study was to determine the efficacy of catheter ablation for AF and the LV function and quality-of-life (QOL) benefits from the ablation outcome in patients with isolated LV diastolic dysfunction compared with systolic dysfunction.
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Methods
Patient Population
From November 2000 to September 2007, 1384 symptomatic patients undergoing AF ablation at Mayo Clinic (Rochester, MN) were enrolled in a longitudinal study to prospectively follow their ablative outcomes, as approved by the Mayo Clinic Institutional Review Board. Each patient had highly symptomatic paroxysmal, persistent, or permanent AF. 9 Based on prospectively acquired clinical data, patients with isolated LV diastolic dysfunction (as defined by echocardiographic criteria) were retrospectively identified by searching the database for LV ejection fraction (LVEF) Ն50% and abnormal diastolic function that could be quantified as grades 1 to 4. Of these patients, 157 had isolated LV diastolic function impairment with preserved LV systolic function (LV diastolic dysfunction group), and 111 had LV systolic dysfunction with LVEF of Յ40% (LV systolic dysfunction group). One hundred ablation recipients who had normal LV systolic (LVEF Ͼ50%) and diastolic function were randomly selected and served as the normal LV function group. No specific matching was performed. Patients were excluded from the study for a variety of reasons, including (1) an LVEF in a range that did not fit into any group (40% to 50%) and (2) the absence of diastolic dysfunction information at baseline in the presence of AF at the time of echocardiogram, indeterminate diastolic dysfunctional grades, very severe systolic dysfunction, or the lack of a baseline transthoracic echocardiogram.
Clinical Evaluation
Before ablative intervention, all patients underwent clinical evaluation, including (1) a detailed history of cardiovascular comorbidities, including HF, and a physical examination; (2) 12-lead electrocardiography; (3) 24-hour Holter monitoring; (4) chest radiography; (5) multislice CT scan; and (6) transesophageal and transthoracic 2D and Doppler echocardiography for complete assessment of LV function.
Baseline Assessment of LV Function
LV systolic function and volumes were quantified from LV enddiastolic and systolic dimensions. Diastolic function was assessed principally using transmitral flow profile from the apical 4-chamber view, including peak E velocity, peak A velocity, E/A ratio, and mitral valve deceleration time as well as tissue Doppler velocity of the mitral annulus (EЈ and AЈ) to assess underlying myopathy. LV filling pressures were estimated by septal and lateral E/EЈ. Using laboratory standards, the interpreting echocardiographer graded diastolic function as normal (grade 0) or abnormal (grades 1 to 4, with a higher number indicating worse severity). A trained observer, blinded to ablative outcome, retrospectively reanalyzed all diastolic grading for consistency and accuracy. General grading criteria are detailed as follows, consistent with the American Society of Echocardiography guidelines 10 
Catheterization and Radiofrequency Ablation
Catheter Placement
All patients underwent ablation under general anesthesia. Patients underwent standard catheterization with placement of 5-F or 6-F catheters into the right ventricle, right atrium, and His bundle region, and a 20-pole catheter was advanced into the coronary sinus. LA access was obtained using a double transseptal puncture technique with 2 8-F sheaths advanced into the LA. A 10-pole circular mapping catheter (Lasso; Biosense Webster; Diamond Bar, CA) was advanced through 1 transseptal sheath to engage each pulmonary vein (PV). An 8-F ablation catheter was advanced through the second sheath for radiofrequency (RF) energy delivery. Intravenous heparin was titrated to maintain the activated clotting time between 300 and 400 s after sheath placement to the end of the procedure. All surface and intracardiac electrograms were recorded on a 48-multichannel electrophysiology workstation (Prucka CardioLab EP System; GE Healthcare; Waukesha, WI). A 10-F intracardiac ultrasound catheter was positioned in the right atrium to guide transseptal catheterization, establish the venoatrial junction, guide catheter positioning, and monitor for pericardial effusion and other complications.
AF Ablation Approach
Lasso-Guided Circumferential PV Isolation
In patients undergoing PV isolation, circumferential ablation outside the PV ostium was guided exclusively by a circular mapping catheter positioned at the PV orifice under intracardiac echocardiographic guidance. RF energy was delivered in the atrial tissue near the venoatrial junction through a 5-mm-tip catheter. Up to 30 W of RF (500 kHz) power (temperature capped at 48°C to 50°C) was delivered for up to 20 to 30 s until the local PV potentials were eliminated. The PV ostia were circumferentially isolated to achieve entrance block as the acute end point.
Wide-Area Circumferential Ablation
The geometry of the native PV anatomy was rendered using a standard electroanatomic system (Carto XP EP Navigation System; Biosense Webster). An electroanatomic map of the LA also was created. The anatomic location of the esophagus as guided by esophageal temperature probes on biplane fluoroscopy was annotated on the posterior surface of the LA map. Substrate ablation was accomplished using a wide-area circumferential ablation ring placed 5 to 15 mm outside the venoatrial junction of the PVs, with up to 30 to 55 W (temperature capped at 50°C to 55°C) delivered through a nonirrigation 8-mm-tip ablation catheter or with up to 25 to 40 W (with a maximum temperature of 42°C) during saline flow at 15 to 30 mL/min delivered through a 3.5-mm-tip open-irrigation catheter. If complete entrance block was not accomplished at the end of wide-area circumferential ablation, additional "touch-up" ablation of residual activity at the PV orifice was guided by a circular mapping catheter. The entrance block with complete elimination of all PV potentials was considered an end point. In patients with persistent or permanent AF, linear lesions were then crafted along the LA roof and from the left inferior PV ring to the mitral valve annulus. Non-PV foci were sought by burst pacing with intravenous infusion of isoproterenol 2 to 10 g/min. Further ablation of arrhythmogenic foci, principally within the superior vena cava, vein of Marshall, and coronary sinus, was undertaken only if localized early recurrent AF was documented. After accomplishing AF ablation, all patients underwent cavotricuspid isthmus ablation for prevention of isthmus-dependent flutter.
Patient Follow-Up
All patients were hospitalized for at least 24 hours, and 12-lead electrocardiography, chest radiography, and transthoracic echocardiography were repeated. All patients were discharged on warfarin with low-molecular-weight heparin bridging until a target international normalized ratio of 2 to 3 was reached. Patients were instructed to return for follow-up 3 months after ablation. At 3 months, patients underwent a detailed physical examination, 12-lead electrocardiography, 24-hour Holter monitoring, CT of the chest, and event monitoring as needed. In addition, a 1-year follow-up visit was standard. Annual assessment of rhythm status and symptoms as well as of antiarrhythmic drug (AAD) use status was performed with clinical follow-up and an annual questionnaire that included QOL assessment. Any atrial arrhythmia after a 2-month blanking period was considered a recurrence. Between visits, designated research and clinical support staff facilitated telephone or written correspondence as clinically warranted among patients, referring clinicians, and the Mayo Clinic electrophysiologist.
QOL Assessment
QOL was evaluated by using the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36). The SF-36 assesses 8 aspects of health status: general and mental health, physical and social functioning, physical and emotional role, pain, and vitality. By using this score system, we intended to relate objective physiological measures, such as the frequency, duration, and intensity of AF episodes, and the degree of symptomatic HF to subjective QOL. These evaluations were performed before the procedure and at 3-month and 1-year follow-up.
Statistical Analysis
Continuous variables are presented as medians with 25th and 75th percentiles. Comparison between groups was performed using the nonparametric Kruskal-Wallis tests. Categorical variables were assessed using Fisher exact test. When significant, all possible comparisons among groups were completed using individual Wilcoxon rank sum test and Fisher exact test, adjusting the individual P values for Ն3 comparisons using the Bonferroni method. Comparisons between the continuous parameters before and after the ablation were completed using the Wilcoxon signed rank test. Comparisons of QOL at follow-up with baseline were performed using paired t tests. AF-free survival after last ablation was estimated using the Kaplan-Meier method. A log-rank test was used to compare estimates between groups. Univariate and multivariable predictors were identified using Cox proportional hazards regression methods. Multivariable models were performed using a stepwise selection of significant univariate values from baseline characteristics. Systolic dysfunction and diastolic dysfunction were forced into the model. Relative risks are expressed as hazard ratios (HRs) with 95% CIs. Analyses were performed using SAS release 8.2 (SAS Institute Inc; Cary, NC) statistical software. A PϽ0.05 was considered significant.
Results
Patient Characteristics
Overall, 368 patients were followed for a median (25th, 75th percentile) follow-up time of 1.1 years (0.4, 2.1 years). The baseline characteristics of the LV systolic dysfunction (nϭ111), isolated LV diastolic dysfunction (nϭ157), and normal LV function (nϭ100) groups were compared as shown in Table 1 . Notable differences in clinical characteristics in the LV dysfunction groups compared with the normal LV function group included (1) older age in patients with diastolic dysfunction, (2) a higher proportion of patients with persistent or longstanding persistent AF in the systolic and diastolic dysfunction groups, and (3) a greater proportion of patients with hypertension in the diastolic dysfunction group.
In the systolic dysfunction group, the median (25th, 75th percentile) LVEF was 35 (30, 40) compared with 63 (60, 65) in controls (PϽ0.001). In the diastolic dysfunction group, the median diastolic functional grade was 2 (2, 2). Increased LA volume index was significant in both systolic and diastolic dysfunction groups compared with those with normal LV function (PϽ0.001).
From a procedural standpoint, substrate-based ablation through a wide-area circumferential ablation approach (often with linear ablation) was used more commonly in patients with LV systolic dysfunction (82%) or diastolic dysfunction (78%) than in those with normal LV function (61%, Pϭ0.001). Repeat ablation rates were similar across the groups (20% systolic dysfunction, 12% diastolic dysfunction, 13% normal LV function, Pϭ0.18).
AF Elimination and Control Using AADs
One-year ablative efficacy outcomes for patients after their final AF ablation are shown in Figure 1 . Follow-up rates were similar in the 3 groups (75% normal LV, 75% diastolic dysfunction, 77% systolic dysfunction). AF elimination rates differed significantly among the groups (Pϭ0.007), but differences in AF control rates only tended to significance (Pϭ0.08). Compared with the 1-year AAD-free AF elimination rate of 84% in patients with normal LV function, the AF elimination rate was significantly lower in patients with systolic dysfunction (62%, Pϭ0.002) and nonsignificantly lower in those with diastolic dysfunction (75%, Pϭ0. 15) . Figure 1 also demonstrates AF control outcomes on or off AADs at 1 year after final ablation. At 1 year, compared with the AF control rate of 89% in patients with normal LV function, the AF control rate was significantly lower in those with systolic dysfunction (76%, Pϭ0.03) but not significantly different in patients with diastolic dysfunction (85%, Pϭ0.35).
Long-Term Ablation Efficacy in Systolic and Diastolic Dysfunction
Estimates of long-term freedom from recurrence after last AF ablation are demonstrated in the Kaplan-Meier curve in Figure 2 . Overall, there was a significant difference in the freedom from recurrence on or off AADs among the 3 groups (Pϭ0.03). Significant differences between the systolic dysfunction and normal LV function groups (Pϭ0.01) and the diastolic dysfunction and normal LV function groups (Pϭ0.01) were identified. At 5 years, overall freedom from any recurrence on or off AADs was 65% in the control patients compared with 33% in the systolic dysfunction group and 40% in the diastolic dysfunction group.
In addition, the difference in overall freedom from recurrence off AADs among the 3 groups was nearly significant (Pϭ0.09). Although no significant differences between the systolic dysfunction and normal LV groups (Pϭ0.13) were observed, there was a significant difference between the control and diastolic dysfunction groups (Pϭ0.03). The corresponding 5-year freedom from recurrence off any AAD was 46% in control patients compared with 26% of patients in the systolic dysfunction group and 29% in the diastolic dysfunction group.
Contribution of LV Systolic and Diastolic Dysfunction to Recurrence
Univariate analysis was performed to assess for contributors to recurrence among the clinical and echocardiographic characteristics listed in Table 2 . The presence of LV systolic dysfunction (LVEF Յ40%) or isolated LV diastolic dysfunction (as opposed to normal LV function) was a significant univariate predictor for recurrence after last ablation. Additional univariate contributors to recurrence included older age, coronary artery disease, and moderate or severe LA enlargement. Protective factors included male sex and paroxysmal AF.
In a multivariable model for recurrence using a stepwise selection process and incorporating systolic and diastolic dysfunction into the model, systolic dysfunction (HR, 1.8; 95% CI, 1.1 to 3.1; Pϭ0.02) and diastolic dysfunction (HR, 1.7; 95% CI, 1.0 to 2.7; Pϭ0.04) remained significant predictors of increased recurrence risk, whereas male sex (HR, 0.5; 95% CI, 0.3 to 0.8; Pϭ0.004) and paroxysmal AF (HR, 0.6; 95% CI, 0.4 to 0.9; Pϭ0.03) were associated with less recurrence risk ( Table 2) .
LV Functional Improvements After Ablation
The systolic dysfunction group had an increase in LVEF from a median of 35% to 56% (PϽ0.001). An increase in LVEF of Ͼ5% after ablation occurred in 49% of the systolic dysfunction group, and 64% of this group achieved near normalization of LVEF to Ն50% (PϽ0.001 compared to other groups for both comparisons). The 1-year AF elimination rate off AADs was 71% in patients with LVEF near normalization compared with 26% in those without (Pϭ0.001).
In patients with isolated LV diastolic dysfunction, 30% demonstrated at least 1 grade improvement in diastolic dysfunction, 62% experienced no change, and 8% had worsened diastolic functional grade. Median LV diastolic functional grade decreased from 2 (2, 2) to 2 (1, 3) (PϽ0.001) compared with an increase from 0 (0, 0) to 0 (0, 1) (PϽ0.001) in the normal LV function group. The 1-year AF elimination rate off AADs was 80% in patients with at least a 1-grade improvement in diastolic function, which did not differ significantly from those with unchanged diastolic function (74%, Pϭ0.53). 
QOL Outcome
Procedural Safety
A comparison of ablation characteristics and procedural complications is shown in Table 3 . The number of RF deliveries was higher in the systolic dysfunction group compared with the diastolic dysfunction and control groups (PϽ0.001). However, major procedure-related complications were similar among the 3 groups.
Discussion
It is uncertain whether AF management in various forms of LV function or dysfunction should be treated the same. To our knowledge, this is the first comprehensive study of the long-term outcomes of AF ablation in patients with both systolic LV dysfunction and isolated LV diastolic dysfunction. This investigation demonstrated a 1-year AF elimination (including atrial tachycardia) rate of 75% in patients with isolated LV diastolic dysfunction. This rate was higher than the 62% AF elimination rate observed in patients with LV systolic dysfunction but was comparable to the success rate observed in the patients with normal LV function. The 5-year freedom from AF recurrence rate was lower in the LV systolic and diastolic dysfunction groups compared with the normal LV function group, despite similar repeat ablation rates. From a reverse-remodeling standpoint, however, patients with LV systolic dysfunction appeared to have the most to gain, demonstrating robust improvements in LVEF to normal or near normal in 40% of the group compared with the diastolic dysfunction group in which more modest, patient-specific diastolic function improvements were seen in less than one third.
AF Ablation as a Management Strategy in Diastolic Dysfunction
There are no specific recommendations for the management of AF in diastolic dysfunction, although there is increasing recognition that patients with isolated diastolic dysfunction represent a unique clinical substrate with an increased risk for HF hospitalization and mortality. [12] [13] [14] Frequently elderly or hypertensive, these patients have noncompliant, stiffened LVs that give rise to elevated LA pressure and LA enlargement, conditions predisposing to AF. 15, 16 The current information about the severity of diastolic dysfunction at the time of presentation for ablation is minimal. 17 In the present population, most patients with diastolic abnormalities had moderate (or grade 2) diastolic dysfunction). Although there are data to show that even patients with only mild impairments in diastolic dysfunction present with a first episode of AF, it is not unexpected that symptomatology requiring ablation would be associated with greater diastolic dysfunction. 6 The present report demonstrates that AF ablation in patients with diastolic dysfunction is relatively efficacious in the midterm, with respective 1-year AF-free rates without and with AADs of 75% and 85%. However, with a 5-year atrial arrhythmia-free rate of 40% after their last ablation by Kaplan-Meier analysis, the long-term ablative efficacy in these patients may be compromised by their contributing cardiovascular comorbidities. Although the diastolic dysfunction and normal LV function groups were not matched in this study, it is notable that, as expected, the diastolic dysfunction group was older and had more hypertension than the normal LV function group. Both variables could account for the progression of LV diastolic dysfunction and the redevelopment of vulnerable atrial substrate that would predispose to AF recurrence, suggesting that effective management of hypertension and maintaining therapies directed toward LV diastolic dysfunction remain important adjuncts to the ablative strategy in achieving long-term sinus rhythm. The present findings are consistent with a recent study of 35 patients in whom the presence of any diastolic abnormality and LA scarring by voltage were predictive of greater recurrence rates. 17
AF Ablation as a Management Strategy in Systolic Dysfunction
In patients with systolic dysfunction, there are specific pharmacological recommendations of the first-line rhythm management of AF. However, amiodarone-a frequent choice-only has an efficacy of Ϸ60% and the risk of toxic adverse effects. 18 -21 In the present study, a 1-year ablative success rate of 62% without AADs (and 76% with or without them) in patients with LV systolic dysfunction refractory to AADs was comparable to the reported AF elimination rates from 69% to 73% at 1 year in similar populations with low LVEF. 7, 8, 22 One important difference in our ablation strategy compared with that of others was a lower repeat ablation rate of 20% versus 40% to 50% in other studies. 7, 8, 22 In this group with systolic dysfunction and a low repeat ablation rate, one third remained free of any atrial arrhythmia recurrence at 5 years. These patients often have coexisting LV diastolic dysfunction, predisposing to LA enlargement, and thus a tendency to persistent AF. Additional LA linear ablations were performed more often in these patients, which may be beneficial for modifying the atrial substrate. An opposing opinion is that this preference may be proarrhythmic. 23, 24 
Reversibility of Left-Sided Cardiomyopathy With Ablation
We were able to demonstrate the extent of reversibility of the myopathic process in patients with LV dysfunction. It has Table 1 .
*Variables were selected out using a stepwise selection process and were not included in the final model. been shown that in patients with lone AF, subtle abnormalities of systolic and diastolic function are present that improve after AF ablation. 25, 26 In the present study, we found that a clinically meaningful increment of improvement in LVEF (by 5%) after ablation occurred in the majority of patients with systolic dysfunction. One third of patients with LV systolic dysfunction appeared to have tachycardia-induced cardiomyopathy, given the restoration of LVEF to normal or near normal after ablation. Ablative efficacy was higher in patients with normalization of LVEF compared with those without normalization of LVEF. Another third of patients who experienced modest LVEF improvement without complete normalization likely represents a group whose primary cardiomyopathy is aggravated by tachyarrhythmia.
In contrast to those in the systolic dysfunction group, the effect of AF ablation on patients with isolated diastolic dysfunction was more difficult to discern. Improvements of potential clinical significance, by at least 1 diastolic grade, were seen in 30%, whereas a decline by 1 grade was only seen in 8%. It is possible that diastolic grade parameters (with only grades 0 to 4) are not sufficiently sensitive to detect subtle changes in diastolic function and that the need for sinus rhythm to assess transmitral inflow confounded serial diastology assessments in this population. Nonetheless, given that our patients with normal LV function still demonstrated some progression to diastolic abnormalities after ablation, it is best assumed that ablation of AF does not predictably reverse diastolic abnormalities, although significant diastolic improvements may be observed in some patients.
Restoring Sinus Rhythm and QOL Improvement
Patients with AF have markedly impaired QOL. 26, 27 In contrast to the echocardiographic improvements after ablation, a marked QOL improvement was more consistent in all states of normal and abnormal LV function. In the present study, a significant improvement in physical composite scores was seen in patients with normal LV function, systolic dysfunction, and diastolic dysfunction. Interestingly, physical QOL in patients with diastolic dysfunction never fully im-proved to the level achieved in those with normal function and systolic dysfunction, who demonstrated the greatest physical health impairment at baseline. This suggests that despite broad-based improvements in QOL, there may be some underlying QOL impairments attributable to comorbid conditions that cannot be overcome by restoration of sinus rhythm.
Procedural Safety
One important final observation is that AF ablation is relatively safe in patients with LV diastolic and systolic abnormalities. The overall rate of procedural complications was similar in patients with normal LV function and those with systolic or diastolic dysfunction. This finding should reassure practitioners concerned about the periprocedural risks of AF ablation in patients with complex conditions.
Study Limitations
There are some limitations to interpreting these data. First, this study was not randomized; therefore, investigator bias could have affected the selection of patients for ablation. In addition, the decision to perform PV isolation and wide-area circumferential ablation typically reflected an operator's approach rather than selection bias. However, the decision to perform linear ablation or additional focal ablation was tailored to a given patient by the combination of patient substrate (moderate to severe LA enlargement, the persistence of AF, a history of previous ablation) and intraprocedure observations (eg, early recurrence of AF or atrial flutter). This approach resulted in more linear ablations performed in the diastolic and systolic dysfunction groups compared with the normal LV function group. Although this reflects our standard of care, a differential ablative approach could confound comparisons between the LV dysfunction and normal LV groups, particularly in light of concerns that incomplete linear ablation can be proarrhythmic.
A second limitation of this study is that the efficacy data reflect elimination of all symptomatic AF and asymptomatic arrhythmia recorded by 24-hour Holter monitoring and event recorder tracings. Importantly, the same approach of 3-month Diaphragmatic paralysis 0 (0) 0 (0) 1 (Ͻ1) 1.0
Esophageal atrial fistula 0 (0) 0 (0) 0 (0) . . .
Data are presented as median (25th, 75th percentile) or n (%). Pairwise differences were adjusted for 3 comparisons using the Bonferroni correction. Abbreviation as in Table 1 .
*PϽ0.05 for the normal vs systolic group. †PϽ0.05 for the diastolic vs systolic group. and 1-year electrophysiology follow-ups was recommended for all patients, allowing for consistent comparison of 1-year results among groups without significant differences observed in follow-up rates. However, we cannot exclude the possibility of asymptomatic AF that was not recorded. Patients with LV systolic or diastolic dysfunction may be more symptomatic with AF recurrence, whereas those with normal LV function may have less detection of asymptomatic AF.
Conclusions
RF ablation of AF is a nonpharmacological option to achieve rhythm control in patients with underlying LV dysfunction. Although AF ablation is less efficacious in patients with LV systolic dysfunction than it is in patients with normal function, its efficacy is comparable to or better than current AAD options, with a low, finite procedural risk, the potential to restore LV systolic function, and improved QOL. In patients with isolated diastolic dysfunction, 1-year AF ablation outcomes are as favorable as those in patients with normal function, but with echocardiographic improvement in a minority and potential for long-term recurrence that is similar to patients with systolic dysfunction.
